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-furfuryladenine (kinetin) is a cytokinin growth factor with several biological effects observed in 
human cells and fruit flies. Kinetin exists naturally in the DNA of almost all organisms tested so far, 
including human cells and various plants. The cytotoxicity effect of kinetin on MCF-7 breast cancer cell 
lines was measured by the sulforhodamine B (SRB) assay and the results showed that kinetin could 
inhibit cell growth in a dose-dependent manner with an IC50 value of 52 µmol/L at 96 h after the drug 
was added into the culture. The interaction of bovine serum albumin (BSA) with kinetin was studied in 
aqueous solution at physiological conditions, using constant protein concentration and various drug 
contents. UV-vis spectroscopic method was used to determine kinetin binding mode, the binding 
constant and the effects of kinetin complexation on protein structure. The spectroscopic results 















Cytokinins are purine derivatives with potential anticancer 
activity, originally discovered as phytohormones that 
promote cell division, leaf expansion and callus cell 
redifferentiation. Early and recent experimental evidence 
suggests that naturally occurring and synthetic cytokinins 
target human cancer cells through antiproliferative, 
apoptogenic and differentiation-inducing activities (Ishii et 
al., 2002; Dolezal et al., 2007; Spinola et al., 2007; 
Bifulco et al., 2008; Cabello et al., 2009; Laezza et al., 
2010; Ottria et al., 2010; Voller et al., 2010; Rajabi et al., 
2010). N
6
-furfuryladenine (kinetin, Figure 1) was first 
isolated and identified in 1955 (Miller et al., 1955) from 
DNA as an artifactual rearrangement product of the 
autoclaving process and as a molecule with multiple 
biological activities (Barciszewski et al., 2007). Since then 
this compound has been widely used as a synthetic 
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applications in biotechnology and cell biology (Rakwal et 
al., 2003). Most importantly, kinetin also exerts anti 
ageing effects on plants, as well as on human skin cells 
and fruitflies (Rattan et al., 1994; Sharma et al., 1995). 
Nevertheless, It is expected that an anticancer activity 
may be express by kinetin in which previous studies 
showed their biological activities and little is known about 
anticancer activity of kinetin against MCF-7 breast cancer 
cell line which was derived from a pleural effusion of a 
patient with metastatic breast cancer and was later 
recognized as the first hormone-responsive breast cancer 
cell line (Soule et al., 1973). The usefulness of the MCF-7 
cell line as an investigative tool led to its adoption in 
laboratories worldwide and several decades of use in 
independent laboratories have facilitated the evolution of 
distinct MCF-7 lineages (Levenson and Jordan, 1997; 
Gooch and Yee, 1999). 
Serum albumins are the major soluble protein 
constituents of the circulatory system and have many 
physiological functions. Binding to albumin is an 
important factor in the solubilization and transportation of 














for serum albumin, and show preferential binding sites on 
serum albumin which may find important therapeutical 
applications. The most important property of this group of 
proteins is that they serve as transporters for a variety of 
compounds. Bovine serum albumin (BSA) (Figure 2) has 
been one of the most extensively studied of this group of 
proteins, particularly because of its structural homology 
with human serum albumin (HSA) (Gelamo et al., 2002; 
Flarakos et al., 2005; Wang et al., 2007). 
In this study, antiproliferative activity of kinetin against 
MCF-7 breast cancer cell line was studied by 
sulforhodamine B (SRB) assay. As a complementary 
information related to the antiproliferative activity, kinetin 
interaction with BSA has been studied, while analyzing 
absorbance changes in the UV-vis frequency range with 
the aim to obtain structural information regarding the 
kinetin binding mode, apparent binding constant and the 
effects of conformational changes of native BSA after 
complexation with kinetin. 
 
 
MATERIALS AND METHODS 
 
Trypsin, trypan blue, antibiotic and antimycotic agent, fetal bovine 
serum (FBS), SRB, dimethyl sulfoxide (DMSO) and BSA were 
purchased from Sigma Chemical Co. (St. Louis, MO). Chemicals 





Human breast cancer MCF-7 cells were supplied from American 
Type Cell Culture Collection and were maintained in the standard 
medium and grown as a monolayer in Dulbecco’s Modified Eagle 
Medium (DMEM) containing 10% FBS, 2 mM glutamine, 100 
units/ml  penicillin  and  100   µg/ml   streptomycin.   Cultures   were  






Figure 2. Structure of bovine serum albumin. 
 
 
maintained at 37°C with 5% CO2 in a humidified atmosphere. 
 
 
In vitro evaluation of cytotoxic activity 
 
Growth activity of kinetin in vitro was evaluated by the SRB assay 
which was used for cell density determination, based on the 
measurement of cellular protein content. SRB is a bright pink 
aminoxanthene dye with two sulfonic groups. Under mild acidic 
conditions, SRB binds to the proteins basic amino acid residues in 
TCA (trichloro acetic acid) fixed cells to provide a sensitive index 
and cellular protein content that is linear over a cell density range of 
at least two orders of magnitude (Vichai and Kirtikara, 2006). 
Kinetin stock solution (10 mM in DMSO) was stored at 4°C and 
diluted with DMEM up to 0.1 to 1 mM range at room temperature 
before treatment. The final percentage of DMSO in the reaction 
mixture was less than 1% (v/v). Cancer cells (2 x 10
3
 cells/well) 
were plated in 96-wells plates and incubated in medium for 24 h. 
Serial dilutions of individual compounds were added. The plates 
were incubated at 37°C, for 96 h prior to addition of kinetin. The 
assay was terminated by the addition of 50 µl of ice-cold 
trichloroacetic acid (final concentration, 10% TCA) and incubated 
for 60 min at 4°C.  
The plates were washed five times with distilled water and air-dried. 
SRB solution (50 µl) at 0.4% (w/v) in 1% acetic acid was added to 
each of the wells, and plates were incubated for 30 min at room 
temperature. The residual dye was removed by washing five times 
with 1% acetic acid. The plates were air-dried or under hood. 
Bound stain was subsequently eluted with 10 mM Trizma base, and 
the absorbance was read on an ELISA plate reader at a wavelength 
of 540 nm and used as a relative measure of viable cell number. 
The percentage of growth inhibition was calculated by using the 
equation: percentage growth inhibition (1 - At/Ac) x 100, where, At 
and Ac represent the absorbance in treated and control cultures, 
respectively. IC50 was determined by interpolation from dose-
response curves. 




Evaluation of cell morphology 
 
MCF-7 cells, plated at about 20,000 cells/well on chamber slides (8 
wells), were treated with 0, 10, 50 and 100 M of kinetin for 96 h. 
After rinsing in PBS, cells were fixed in methanol and stained with 




Binding study of BSA 
 
Purified BSA “essentially globulin and fatty acid free” (Aplichem Co. 
Germany) was used to prepare the stock 2.5 × 10
−5
 M solution by 
dissolving an appropriate amount of BSA in 0.05 mol L
-1
 Tris-HCl 
buffer of pH 7.4 containing 0.1 M NaCl solution, then stored at 4°C. 
The purity of BSA stock solution (10 × 10
−3
 M in DMSO) was 
estimated to be 99% based on an absorbance value at 279 nm 
using a reference value of 0.667 for 1.0 g L
−1
 of pure BSA. All stock 
solutions were stored at 4°C in the dark. All solutions in this study 
were diluted to the required volume with Tris–HCl buffer of pH 7.4. 
All other reagents involved in this study were of analytical-reagent 
grade, and doubly distilled water was used throughout. UV-vis 
absorption spectra were measured on a Beckman UV 
spectrophotometer with the use of a 10 mm quartz cuvette. 
 
 
RESULTS AND DISSCUSION  
 
Cytotoxicity evaluation of kinetin in vitro 
 
The human breast cancer cell line MCF-7 provides an 
unlimited source of homogenous self-replicating material, 
free of contaminating stromal cells, and can be easily 
cultured in simple standard media. Such a cell line is 
ideal to study the interaction between a chemopreventive 
drug and a cancer cell. The mechanism by which a 
chemopreventive drug inhibits the proliferation of a 
cancer cell can be best studied in vitro where the other 
physiological regulatory mechanisms, which are present 
in the in vivo system, are absent. In vitro studies provide 
the advantages, from an experimental point of view, of 
being able to observe cells and tissues in isolation and 
away from the controlling and modifying influences of 
other tissues in the body. In the presence of different 
doses of kinetin, the cells were inhibited ranging from 10 
to 90% with a loss of viable cells (Figure 3). Kinetin 
inhibited the proliferation of MCF-7 cells in a 
concentration and time-dependent manner. The viability 
of the MCF-7 cells was unaffected by less than 5 µmol/L 
kinetin treatment for 96 h, but changed to 95%, in 
response to 10 µmol/L kinetin, respectively. However, 
viability decreased to 50% in response to 52 µmol/L 
kinetin and continued to decrease as the concentration of 
kinetin was increased, and was 10% with 100 µmol/L and 
5% with 150 µmol/L kinetin exposure. Thus, it was 
evident that kinetin up to a dose of 20 µmol/L was almost 
non-cytotoxic in vitro. The MCF-7 cells were viable up to 
95% at the maximum effective dose of kinetin 10 µmol/L 
used in the study and viability of control was taken as 
100%. The concentration which causes 50% inhibition of 





employing SRB assay (Figure 3B). Further research is 
required in order to demonstrate that this antiproliferative 
effect may be related to apoptosis and cell cycle arrest. 
 
 
Cell morphology and shape study 
 
For more than 150 years, morphological features played 
the leading role in the description of cell death. However, 
during the past three decades, cell death has been 
characterized on the molecular level, which markedly 
increased our understanding of the morphology under 
inverted microscope, cell shape and its changes can be 
observed clearly. Treated and untreated (control) cells 
were viewed using an inverted phase-contrast 
microscope model Zeiss and photographed using a Nikon 
camera attached to the microscope. Figure 3c shows the 
incubation of the cells with different concentrations of 
kinetin after 96 h treatment. Cells in the control group 
were regular polygonal and cell antennas were short and 
there were very few round cells. Cells treated with kinetin 
for 4 days showed obvious morphological changes, 
including the loss of adhesion, rounding and sporadical 
distribution, and there was clear concentration-response 
tendency, indicating the possibility of apoptosis 
occurrence. Further staining for fluorescence microscopic 
studies is required to determine whether the cytotoxic 
effects and morphological alternations of kinetin were 
related to the induction of apoptosis. 
 
 
Absorption spectra of kinetin-BSA complexes  
 
The UV spectra of free kinetin and BSA are reported in 
comparison with kinetin-BSA complex (Figure 4). The 
increase in intensity of kinetin characteristic UV-vis band 
at 279 nm is due to major drug-BSA interaction (Nafisi et 
al., 2008). 
The calculation of the overall binding constants was 
carried out on the basis of UV absorption as reported 
(Figure 5). The equilibrium for kinetin and BSA complex 
can be described as follows:  
 








The double reciprocal plot of 1/[A-A0] vs 1/[ligand] is 
linear and the association binding constant (K) is 
calculated from the ratio of the intercept on the vertical 
coordinate axis to the slope. A0 is the initial absorption of 
the free BSA at 279 nm and A is the recorded absorption 
at different kinetin concentrations (L).  
The overall binding constant K for kinetin-BSA 




. The value 
obtained is indicative of a good kinetin-protein interaction. 
The reason for the low stability of the kinetin-BSA com-























Figure 3. Effects of kinetin on the proliferation of MCF-7. A and B: The percentage of growth inhibition was 
calculated by using the equation: (1- At/Ac) x 100, where At and Ac represent the absorbance in treated and 
control cultures, respectively. IC50 was determined by interpolation from dose-response curves; C: 






Figure 4. UV-vis absorbance spectra of BSA in the presence 
of kinetin. 
plexes can be attributed to the presence of mainly 
hydrogen bonding interaction between protein donor 
atoms and the kinetin polar groups or an indirect drug-





The ability to induce cancer cell death is an important 
property of a candidate anticancer drug. The process of 
cytotoxicity is characterized by specific biochemical 
assays and morphological changes. This study 
demonstrates the antiproliferative properties of kinetin 
toward MCF-7 human breast cancer cells by the SRB 
assay and the results showed that kinetin displayed good 
cytotoxic effect against MCF-7 and could inhibit cell 
growth in a dose-dependent manner with an IC50 value 
of52 µM at 96 h after the drug was added into the culture.  






Figure 5. The plot of 1/(A-A0) vs 1/L for BSA and kinetin 
complexes where A0 is the initial protein absorption band (279 




The cell viability result showed that the MCF-7 cells were 
sensitive to the toxic higher doses of kinetin than to the 
low doses. From this results, we strongly suggest the 
selection of >50 µM concentration of kinetin due to its 
effect for further studies. The Giemsa staining revealed 
that there is a morphological change in cells, such as loss 
of adhesion, rounding, cell shrinkage and detachment 
from the substratum. Our result from structural analysis 
showed interaction of kinetin with BSA. Since protein-
drug binding greatly influences absorption, distribution, 
metabolism and excretion properties of typical drugs, 
studies on the protein-drug binding is important for the 
elucidation of the reaction mechanisms, providing a 
pathway to the pharmacokinetics and pharmacodynamic 
mechanisms of these substances in various tissues.  
The interaction of BSA with kinetin was studied in 
aqueous solution at physiological conditions, using 
constant protein concentration and various drug contents. 
UV-vis spectroscopic method was used to determine 
ligands’ binding mode, the binding constant and the 
effects of ligand complexation on protein secondary 
structure. UV-vis spectra of BSA indicated that on 
addition of kinetin, the absorption peaks in the visible 
region showed a moderate blue-shift. The overall binding 





 using UV absorption spectroscopy. In 
conclusion, kinetin may have the potentials for inclusion 
in an anticancer drug discovery programme based on its 
role on induction of apoptosis and cell cycle arrest in the 
near future and further research including morphological 
staining studies, biochemical assays and flow cytometric 
analysis are required in order to demonstrate that its 
antiproliferative effects may be related to apoptosis and 
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